Terns Pharmaceuticals (TERN) Competitors $6.06 -0.03 (-0.49%) Closing price 04:00 PM EasternExtended Trading$6.07 +0.01 (+0.17%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. BLTE, IDYA, IMCR, TARS, APGE, OCUL, VCEL, SPRY, ARQT, and ADPTShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), Ocular Therapeutix (OCUL), Vericel (VCEL), ARS Pharmaceuticals (SPRY), Arcutis Biotherapeutics (ARQT), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors Belite Bio IDEAYA Biosciences Immunocore Tarsus Pharmaceuticals Apogee Therapeutics Ocular Therapeutix Vericel ARS Pharmaceuticals Arcutis Biotherapeutics Adaptive Biotechnologies Terns Pharmaceuticals (NASDAQ:TERN) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Does the media favor TERN or BLTE? In the previous week, Belite Bio had 1 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 2 mentions for Belite Bio and 1 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.00 beat Belite Bio's score of -0.50 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Terns Pharmaceuticals Neutral Belite Bio Negative Which has higher earnings and valuation, TERN or BLTE? Belite Bio is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.09-5.56Belite BioN/AN/A-$36.14M-$1.36-45.48 Do analysts rate TERN or BLTE? Terns Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 157.84%. Belite Bio has a consensus price target of $96.67, indicating a potential upside of 56.29%. Given Terns Pharmaceuticals' higher probable upside, equities research analysts plainly believe Terns Pharmaceuticals is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, TERN or BLTE? Terns Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, suggesting that its share price is 250% less volatile than the S&P 500. Do institutionals and insiders hold more shares of TERN or BLTE? 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is TERN or BLTE more profitable? Terns Pharmaceuticals' return on equity of -28.81% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -28.81% -27.55% Belite Bio N/A -32.07%-30.91% SummaryTerns Pharmaceuticals beats Belite Bio on 8 of the 13 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$531.88M$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-5.5620.7327.9019.95Price / SalesN/A321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book1.498.308.635.90Net Income-$88.85M-$55.19M$3.24B$258.42M7 Day Performance8.21%5.07%3.22%1.94%1 Month Performance59.89%17.61%10.72%12.02%1 Year Performance-30.10%7.03%34.94%20.81% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals3.6241 of 5 stars$6.06-0.5%$15.63+157.8%-32.1%$531.88MN/A-5.5640BLTEBelite Bio1.7601 of 5 stars$61.30+0.6%$96.67+57.7%+24.4%$1.94BN/A-45.0710IDYAIDEAYA Biosciences4.1923 of 5 stars$21.81+1.0%$47.55+118.0%-44.9%$1.89B$7M-6.0880News CoverageAnalyst ForecastIMCRImmunocore1.0599 of 5 stars$36.93+1.7%$58.89+59.5%-8.1%$1.82B$310.20M-85.88320News CoverageTARSTarsus Pharmaceuticals1.6687 of 5 stars$42.18-2.5%$66.67+58.1%+51.8%$1.82B$182.95M-15.4550APGEApogee Therapeutics3.4115 of 5 stars$39.11-0.5%$99.00+153.1%-19.6%$1.81BN/A-10.8691Positive NewsOCULOcular Therapeutix3.6427 of 5 stars$11.52+1.7%$17.33+50.5%+48.6%$1.80B$63.72M-10.02230VCELVericel3.8319 of 5 stars$35.46+0.3%$61.14+72.4%-23.7%$1.78B$237.22M1,178.00300News CoveragePositive NewsUpcoming EarningsSPRYARS Pharmaceuticals3.0743 of 5 stars$17.85-0.4%$31.00+73.7%+74.4%$1.76B$89.15M-111.5690ARQTArcutis Biotherapeutics2.2581 of 5 stars$14.34-2.2%$18.80+31.1%+46.2%$1.75B$196.54M-13.79150Positive NewsADPTAdaptive Biotechnologies3.0067 of 5 stars$10.31-0.8%$10.57+2.5%+158.8%$1.58B$178.96M-10.74790 Related Companies and Tools Related Companies Belite Bio Competitors IDEAYA Biosciences Competitors Immunocore Competitors Tarsus Pharmaceuticals Competitors Apogee Therapeutics Competitors Ocular Therapeutix Competitors Vericel Competitors ARS Pharmaceuticals Competitors Arcutis Biotherapeutics Competitors Adaptive Biotechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TERN Stock Alerts